Cerner Corp. (NASDAQ:CERN) — This leading supplier of health care information technology is in a powerful bull channel that began last November.
Analysts expect revenues to increase 14% in 2011, and they expect similar results in 2012. S&P recently upgraded their opinion to a “four-star buy” recommendation with a target of $80. They estimate a three-year earnings growth rate of 24%.
CERN made a new high in September at over $74. The recent pullback to under $66 appears to be an excellent price to purchase shares of this high-growth investment as a long-term hold or a trade to $75.